高盛:給予華領醫藥-B(2552.HK)“買入”評級,目標價12.7港元
格隆匯9月30日丨高盛29日發佈研報,華領醫藥糖尿病緩解的早期數據令人鼓舞,給予其“買入”評級,12個月目標價12.7港元。高盛稱,華醫藥在9月25-27日CBII會議上介紹了研究者發起的DREAM研究。DREAM研究是對未接受額外治療或劇烈運動/飲食控制,以及未接受藥物治療的患者進行的第3期Dorzagliatin單藥治療的更長時間的隨訪研究(SEED研究),以52周時的糖尿病緩解率作為主要終點。數據(n=69)顯示,每個研究者評估的緩解率為65%(HbA1c<7%)或根據ADA共識標準的緩解率為52%(HbA1c<6.5%),β細胞功能和胰島素抵抗有良好趨勢。受這些結果的鼓舞,華領醫藥計劃開展更多的試驗,以評估Dorzagliatin在糖尿病緩解中的作用。雖然初步數據需要在後續研究中進一步測試和驗證,但高盛認為,這些結果是驗證Dorzagliatin可以部分恢復β細胞功能的先前信念的又一步。期待看到更多的數據,以更好地評估潛在的臨牀/商業影響。2022年上半年潛在的NDA批准和潛在的全球合作是該公司發展的關鍵催化劑。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.